Candriam Luxembourg S.C.A. increased its stake in CryoLife Inc. (NYSE:CRY) by 16.3% during the second quarter, Holdings Channel reports. The institutional investor owned 100,000 shares of the company’s stock after buying an additional 14,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in CryoLife were worth $1,181,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CRY. Louisiana State Employees Retirement System boosted its position in CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,400 shares of the company’s stock worth $135,000 after buying an additional 100 shares in the last quarter. Arizona State Retirement System boosted its position in CryoLife by 5.7% in the first quarter. Arizona State Retirement System now owns 13,054 shares of the company’s stock worth $140,000 after buying an additional 700 shares in the last quarter. Spark Investment Management LLC boosted its position in CryoLife by 217.6% in the first quarter. Spark Investment Management LLC now owns 39,700 shares of the company’s stock worth $426,000 after buying an additional 27,200 shares in the last quarter. Prudential Financial Inc. boosted its position in CryoLife by 11.8% in the first quarter. Prudential Financial Inc. now owns 65,404 shares of the company’s stock worth $703,000 after buying an additional 6,881 shares in the last quarter. Finally, Adirondack Research & Management Inc. boosted its position in CryoLife by 1.5% in the first quarter. Adirondack Research & Management Inc. now owns 277,123 shares of the company’s stock worth $2,979,000 after buying an additional 4,200 shares in the last quarter. Hedge funds and other institutional investors own 58.13% of the company’s stock.
CryoLife Inc. (NYSE:CRY) traded down 0.81% on Thursday, reaching $17.10. The company’s stock had a trading volume of 95,570 shares. The stock has a market capitalization of $583.28 million, a P/E ratio of 54.81 and a beta of 1.05. CryoLife Inc. has a 52 week low of $8.94 and a 52 week high of $18.64. The firm has a 50 day moving average price of $16.98 and a 200 day moving average price of $13.41.
CryoLife (NYSE:CRY) last issued its quarterly earnings data on Monday, July 25th. The company reported $0.13 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.11. CryoLife had a net margin of 5.80% and a return on equity of 8.15%. The business earned $47.10 million during the quarter, compared to analysts’ expectations of $35.50 million. During the same period last year, the company posted $0.03 EPS. The company’s revenue was up 32.6% on a year-over-year basis. On average, equities analysts anticipate that CryoLife Inc. will post $0.34 EPS for the current year.
A number of research analysts recently commented on the company. Canaccord Genuity reiterated a “buy” rating on shares of CryoLife in a report on Tuesday, July 26th. Zacks Investment Research cut CryoLife from a “buy” rating to a “hold” rating in a report on Wednesday, July 27th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $16.00 price objective on shares of CryoLife in a report on Wednesday, July 27th. Finally, Lake Street Capital assumed coverage on CryoLife in a report on Wednesday, June 15th. They issued a “buy” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $15.00.
In other news, Director C Elkins Ronald sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $14.00, for a total transaction of $28,000.00. Following the completion of the transaction, the director now directly owns 103,586 shares of the company’s stock, valued at approximately $1,450,204. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 6.08% of the company’s stock.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife Inc. (NYSE:CRY).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.